Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

Answer questions and earn CME/CNE

[1]  Y. J. Choi.  Gastric Extranodal Marginal Zone B-Cell Lymphoma of MALT , 2016 .

[2]  R. Greil,et al.  AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma) , 2015 .

[3]  A. Ferreri,et al.  Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. , 2015, The oncologist.

[4]  A. Ferreri,et al.  High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Yeh,et al.  Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma , 2015, The American journal of surgical pathology.

[6]  C. Portell,et al.  The Role of Infectious Agents, Antibiotics, and Antiviral Therapy in the Treatment of Extranodal Marginal Zone Lymphoma and Other Low-Grade Lymphomas , 2015, Current Treatment Options in Oncology.

[7]  D. Heo,et al.  Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma , 2015, Annals of Hematology.

[8]  A. Chott,et al.  Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up , 2015, Annals of Hematology.

[9]  Juan F. García,et al.  First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. , 2014, The Lancet. Haematology.

[10]  M. Mayerhoefer,et al.  Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients , 2014, PloS one.

[11]  R. Bruno,et al.  Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Mayerhoefer,et al.  Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis , 2014, Annals of Hematology.

[13]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[14]  S. Pileri,et al.  Prevalence of Achromobacter xylosoxidans in pulmonary mucosa‐associated lymphoid tissue lymphoma in different regions of Europe , 2014, British Journal of Haematology.

[15]  J. Cerhan,et al.  Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[16]  M. Mayerhoefer,et al.  Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) , 2014, Annals of Hematology.

[17]  C. Hassan,et al.  Eradication Therapy in Helicobacter pylori-negative, Gastric Low-grade Mucosa–associated Lymphoid Tissue Lymphoma Patients: A Systematic Review , 2013, Journal of clinical gastroenterology.

[18]  M. Raderer,et al.  Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. , 2013, Blood.

[19]  Nayoung Kim,et al.  Characteristics of Helicobacter pylori‐positive and Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma and their influence on clinical outcome , 2013, Helicobacter.

[20]  A. Amiot,et al.  Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study , 2013, Leukemia & lymphoma.

[21]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[22]  W. Dolak,et al.  A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) , 2013, Haematologica.

[23]  D. Strunk,et al.  Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma , 2013, Modern Pathology.

[24]  R. Greil,et al.  Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie , 2013, Haematologica.

[25]  C. Copie-Bergman,et al.  Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Copie-Bergman,et al.  Gela histological scoring system for post‐treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice , 2013, British journal of haematology.

[27]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.

[28]  C. Copie-Bergman,et al.  Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  K. Savage,et al.  Comparative outcomes of oncologic therapy in gastric extranodal marginal zone ( MALT ) lymphoma : analysis of the SEER-Medicare database , 2013 .

[30]  F. Cavalli,et al.  Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  U. Jäger,et al.  Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma , 2012, Haematologica.

[32]  M. Diago,et al.  Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response , 2012, Journal of viral hepatitis.

[33]  R. Talamini,et al.  Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae , 2012, British Journal of Cancer.

[34]  E. Kuipers,et al.  Premalignant gastric lesions in patients with gastric mucosa-associated lymphoid tissue lymphoma and metachronous gastric adenocarcinoma: a case–control study , 2012, European journal of gastroenterology & hepatology.

[35]  Marc Lecuit,et al.  Immunoproliferative small intestinal disease associated with Campylobacter jejuni. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[36]  R. Gascoyne,et al.  Genomic profiles of MALT lymphomas: variability across anatomical sites , 2011, Haematologica.

[37]  A. Chott,et al.  Clinicopathological aspects of mucosa‐associated lymphoid tissue (MALT) lymphoma of the parotid gland: A retrospective single‐center analysis of 28 cases , 2011, Head & neck.

[38]  A. López-Guillermo,et al.  Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  F. Mégraud,et al.  EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT , 2011, Gut.

[40]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[41]  H. Popper,et al.  Chlamydia psittaci Infection in nongastrointestinal extranodal MALT lymphomas and their precursor lesions. , 2011, American journal of clinical pathology.

[42]  A. Ferreri,et al.  Six‐month oral clarithromycin regimen is safe and active in extranodal marginal zone B‐cell lymphomas: final results of a single‐centre phase II trial , 2010, British journal of haematology.

[43]  Dong-Wan Kim,et al.  First‐line therapy with doxycycline in ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors , 2010, Cancer science.

[44]  M. Stolte,et al.  Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[45]  A. Salar,et al.  Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue type , 2009, Cancer.

[46]  C. Doglioni,et al.  Chlamydial infection: the link with ocular adnexal lymphomas , 2009, Nature Reviews Clinical Oncology.

[47]  C. Doglioni,et al.  Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here? , 2009, Blood.

[48]  M. Raderer,et al.  Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  R. Borie,et al.  Clinical characteristics and prognostic factors of pulmonary MALT lymphoma , 2009, European Respiratory Journal.

[50]  C. Hassan,et al.  Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis , 2009, The American Journal of Gastroenterology.

[51]  A. Chott,et al.  A phase II study of bortezomib in patients with MALT lymphoma , 2009, Haematologica.

[52]  C. Copie-Bergman,et al.  Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial , 2009, British journal of haematology.

[53]  M. Binder,et al.  Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  L. Sobin,et al.  t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases , 2009, Modern Pathology.

[55]  L. Pecciarini,et al.  Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: Results of a single‐center prospective case–control study , 2008, International journal of cancer.

[56]  A. Vincent-Salomon,et al.  Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations? , 2008, Anti-cancer drugs.

[57]  I. Lossos,et al.  Ocular adnexal lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis , 2008, British journal of haematology.

[58]  A. Chott,et al.  Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  F. Cavalli,et al.  Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  J. Cerhan,et al.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. , 2008, Blood.

[61]  D. de Jong,et al.  Dissemination patterns in non-gastric MALT lymphoma , 2008, Haematologica.

[62]  A. Nicholson,et al.  Chromosomal translocations involving BCL6 in MALT lymphoma , 2008, Haematologica.

[63]  L. Pecciarini,et al.  Chlamydia-psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  L. Pecciarini,et al.  A woman and her canary: a tale of chlamydiae and lymphomas. , 2007, Journal of the National Cancer Institute.

[65]  K. Turetschek,et al.  Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. , 2007, Anticancer research.

[66]  B. Esmaeli,et al.  Meta–analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics , 2007, Cancer.

[67]  A. Chott,et al.  MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course , 2007, Leukemia.

[68]  W. Fischbach,et al.  Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series , 2007, Gut.

[69]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[70]  S. Swerdlow,et al.  Extranodal Marginal Zone B-cell Lymphomas of the Ocular Adnexa: Multiparameter Analysis of 34 Cases Including Interphase Molecular Cytogenetics and PCR for Chlamydia psittaci , 2007, The American journal of surgical pathology.

[71]  Jian Huang,et al.  The Helicobacter pylori virulence factor CagA promotes Erk1/2‐mediated Bad phosphorylation in lymphocytes: a mechanism of CagA‐inhibited lymphocyte apoptosis , 2007, Cellular microbiology.

[72]  I. Lossos,et al.  Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma , 2007, Leukemia & lymphoma.

[73]  K. Turetschek,et al.  Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma , 2007, Oncology.

[74]  A. Chott,et al.  18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  C. Doglioni,et al.  Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. , 2006, Journal of the National Cancer Institute.

[76]  K. Turetschek,et al.  Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A. Chott,et al.  Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas , 2005, Gut.

[78]  U. Jaeger,et al.  Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Sander R. Dubovy,et al.  Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. , 2005, Blood.

[80]  Y. Matsuno,et al.  Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  K. Sugimura,et al.  Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[82]  C. Doglioni,et al.  Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  M. Hansmann,et al.  Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  U. Jaeger,et al.  High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up , 2005, Clinical Cancer Research.

[85]  A. Chott,et al.  T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma , 2005, Leukemia.

[86]  E. Pedrinis,et al.  Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  A. Nicholson,et al.  MALT lymphoma with t(14;18)(q32;q21)/IGH‐MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression , 2005, The Journal of pathology.

[88]  Atul K. Jain,et al.  MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA WITH INTRAOCULAR INVOLVEMENT , 2005, Retina.

[89]  P. Coffer,et al.  Forkhead-box transcription factors and their role in the immune system , 2004, Nature Reviews Immunology.

[90]  R. Siebert,et al.  Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites , 2004, Leukemia.

[91]  T. Matsuo,et al.  Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. , 2004, Ophthalmology.

[92]  S. Pileri,et al.  Fludarabine‐containing chemotherapy as frontline treatment of nongastrointestinal mucosa‐associated lymphoid tissue lymphoma , 2004, Cancer.

[93]  G. Dewald,et al.  Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1 , 2004, Leukemia.

[94]  O. Lortholary,et al.  Immunoproliferative small intestinal disease associated with Campylobacter jejuni. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[95]  J. Gisbert,et al.  Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. , 2003, Gastroenterology.

[96]  R. Tsang,et al.  Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  F. Cavalli,et al.  Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. , 2003, Blood.

[98]  A. Nicholson,et al.  Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. , 2003, Blood.

[99]  D. de Jong,et al.  Paris staging system for primary gastrointestinal lymphomas , 2003, Gut.

[100]  Peter Marynen,et al.  MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. , 2003, Blood.

[101]  D. Graham,et al.  Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors , 2003, American Journal of Gastroenterology.

[102]  A. López-Guillermo,et al.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.

[103]  F. Mégraud,et al.  Which Test to Use to Detect Helicobacter pylori Infection in Patients With Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma? , 2003, American Journal of Gastroenterology.

[104]  R. Brezinschek,et al.  Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  R. Hamoudi,et al.  T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. , 2001, Blood.

[106]  Ming-Qing Du,et al.  Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy , 2001, The Lancet.

[107]  K. Maclennan,et al.  Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma , 2000, Genes, chromosomes & cancer.

[108]  M. Dyer,et al.  BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. , 2000, The American journal of pathology.

[109]  M. Stolte,et al.  Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. , 2000, Gastroenterology.

[110]  J. Heesemann,et al.  Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation , 2000, Gut.

[111]  R. Tsang,et al.  Mucosa-associated lymphoid tissue lymphomas , 2000, Current oncology reports.

[112]  H. Müller-Hermelink,et al.  Mucosal humoral immune response to CagA shows a high prevalence in patients with gastric MALT-type lymphoma , 2000, Virchows Archiv.

[113]  G. Salles,et al.  Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. , 2000, Blood.

[114]  H. Kerl,et al.  [Therapy of primary cutaneous B-cell lymphomas]. , 2000, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[115]  H. Kerl,et al.  Die Therapie der primären kutanen B-Zell-Lymphome , 2000, Der Hautarzt.

[116]  P. Brandtzaeg,et al.  Regional specialization in the mucosal immune system: primed cells do not always home along the same track. , 1999, Immunology today.

[117]  P. Isaacson.  Gastric MALT lymphoma: from concept to cure. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[118]  M. Fujishima,et al.  B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. , 1998, The American journal of pathology.

[119]  P. Isaacson,et al.  Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. , 1997, The American journal of pathology.

[120]  T. Greiner,et al.  t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[121]  F. Cavalli,et al.  Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. , 1997, Leukemia & lymphoma.

[122]  P. Neumeister,et al.  Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. , 1997, Gastroenterology.

[123]  G. Salles,et al.  Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  F. Strle,et al.  Molecular subtyping of Borrelia burgdorferi sensu lato isolates from five patients with solitary lymphocytoma. , 1997, The Journal of investigative dermatology.

[125]  P. Isaacson,et al.  Intestinal dissemination of gastric mucosa-associated lymphoid tissue lymphoma. , 1996, Blood.

[126]  N. Harris,et al.  Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. , 1996, The American journal of surgical pathology.

[127]  W. Dickey,et al.  Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. , 1996, Alimentary pharmacology & therapeutics.

[128]  Nalini Singh,et al.  Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. , 1996, The American journal of pathology.

[129]  S. Pittaluga,et al.  Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. , 1996, Blood.

[130]  P. Gaulard,et al.  Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  P. Isaacson,et al.  Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. , 1995, Blood.

[132]  M. Piris,et al.  Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  M. Stolte,et al.  Factors influencing lymph node infiltration in primary gastric malignant lymphoma of the mucosa-associated lymphoid tissue. , 1994, Pathology, research and practice.

[134]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[135]  G. Salles,et al.  Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. , 1994, Blood.

[136]  R. Warnke,et al.  Helicobacter pylori infection and gastric lymphoma. , 1994, The New England journal of medicine.

[137]  B. Coiffier,et al.  Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[138]  A. Santoro,et al.  Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[139]  P. Isaacson,et al.  The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori , 1993, The Lancet.

[140]  E. Berg,et al.  α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 , 1993, Cell.

[141]  J. Dalphin,et al.  Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. , 1993, Chest.

[142]  T. Radaszkiewicz,et al.  Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. , 1992, Gastroenterology.

[143]  P. Isaacson,et al.  Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma , 1991, The Lancet.

[144]  P. Isaacson,et al.  Low-grade primary B-cell lymphoma of the lung. An immunohistochemical, molecular, and cytogenetic study of a single case. , 1990, American journal of clinical pathology.

[145]  D. Cunningham,et al.  The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT). , 1989, The American journal of pathology.

[146]  P. Isaacson,et al.  Malignant lymphoma of mucosa‐associated lymphoid tissue. A distinctive type of B‐cell lymphoma , 1983, Cancer.

[147]  B. Marshall,et al.  UNIDENTIFIED CURVED BACILLI ON GASTRIC EPITHELIUM IN ACTIVE CHRONIC GASTRITIS , 1983, The Lancet.